Mark A. Morrissey

Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project

David McHugh, Cynthia A. Cameron, José E. Abdenur et al. · Genetics in Medicine · 2011 · 352 citations · Full text

Medicine, Biochemistry, Mass Spectrometric Analysis +16

Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte

James D. Weisfeld‐Adams, Mark A. Morrissey, Brian Kirmse et al. · Molecular Genetics and Metabolism · 2009 · 132 citations · Full text

Medicine, Biochemistry, Pediatrics +15

Enhanced interpretation of newborn screening results without analyte cutoff values

Gregg Marquardt, Robert J. Currier, David McHugh et al. · Genetics in Medicine · 2012 · 123 citations · Full text

Medicine, Child Health, Pediatrics +14

Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy

Irene C. Huffnagel, Malu-Clair van de Beek, Amanda Showers et al. · Molecular Genetics and Metabolism · 2017 · 73 citations

Medicine, Biochemistry, Pediatrics +8

Implementation of newborn screening for Krabbe disease: Population study and cutoff determination

Joseph J. Orsini, Mark A. Morrissey, Laura N. Slavin et al. · Clinical Biochemistry · 2009 · 54 citations

Medicine, Pediatrics, Preventive Medicine +14